Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.66 CAD | -.--% | +1.54% | -10.81% |
Apr. 25 | Transcript : Valeo Pharma Inc. - Shareholder/Analyst Call | |
Mar. 22 | Valeo Pharma Inc. Announces Appointment of Al Moghaddam to Board of Directors | CI |
Sales 2024 * | 61M 44.59M | Sales 2025 * | 75.83M 55.43M | Capitalization | 11.35M 8.3M |
---|---|---|---|---|---|
Net income 2024 * | -18M -13.16M | Net income 2025 * | -12M -8.77M | EV / Sales 2024 * | 1.05 x |
Net Debt 2024 * | 52.53M 38.4M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.15 x |
P/E ratio 2024 * |
-0.58
x | P/E ratio 2025 * |
-0.88
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.88% |
Latest transcript on Valeo Pharma Inc.
Managers | Title | Age | Since |
---|---|---|---|
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Pascal Tougas
DFI | Director of Finance/CFO | - | Nov. 19 |
Nelly Komari
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard MacKay
CHM | Chairman | 89 | 18-07-24 |
Steven Saviuk
FOU | Founder | 65 | 03-03-26 |
Marc Léger
BRD | Director/Board Member | 65 | 22-04-26 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- VPH Stock
- VPH Stock